Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Garmo

Showing results (191-200 of 261) with videos related to

Pageof 27
Sort By:
Ecancermedicalscience|September 14, 2017
Serum biomarkers to predict risk of testicular and penile cancer in AMORISArunangshu Ghoshal, Hans Garmo, Rhonda Arthur, et al.
BJU International|September 12, 2025
Urinary tract events after radical radiotherapy (RT) for prostate cancer according to pre-RT International Prostate Symptom ScorePaolo Zaurito, Marcus Westerberg, Hans Garmo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2012
Tumor stage affects risk and prognosis of contralateral breast cancer: results from a large Swedish-population-based studyVoralak Vichapat, Hans Garmo, Marit Holmqvist, et al.
Archives of Internal Medicine|May 13, 2009
A comprehensive pharmacist intervention to reduce morbidity in patients 80 years or older: a randomized controlled trialUlrika Gillespie, Anna Alassaad, Dan Henrohn, et al.
BMJ Open|December 29, 2022
Time without PSA recurrence after radical prostatectomy as a predictor of future biochemical recurrence, metastatic disease and prostate cancer death: a prospective Scandinavian cohort studyMats Steinholtz Ahlberg, Hans Garmo, Hans-Olov Adami, et al.
The Lancet. Oncology|April 17, 2010
Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe SwedenMieke Van Hemelrijck, Jan Adolfsson, Hans Garmo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2010
Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe SwedenMieke Van Hemelrijck, Hans Garmo, Lars Holmberg, et al.
Epidemiology (Cambridge, Mass.)|May 3, 2021
An Aggregated Comorbidity Measure Based on History of Filled Drug Prescriptions: Development and Evaluation in Two Separate CohortsRolf Gedeborg, Malin Sund, Mats Lambe, et al.
European Journal of Cancer (Oxford, England : 1990)|April 14, 2011
Gamma-glutamyltransferase and risk of cancer in a cohort of 545,460 persons - the Swedish AMORIS studyMieke Van Hemelrijck, Wayel Jassem, Goran Walldius, et al.
European Urology|March 8, 2013
Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trialAnna Bill-Axelson, Hans Garmo, Lars Holmberg, et al.
Pageof 27

Showing results (191-200 of 261) with videos related to

Sort By:
Pageof 27
Ecancermedicalscience|September 14, 2017
Serum biomarkers to predict risk of testicular and penile cancer in AMORISArunangshu Ghoshal, Hans Garmo, Rhonda Arthur, et al.
BJU International|September 12, 2025
Urinary tract events after radical radiotherapy (RT) for prostate cancer according to pre-RT International Prostate Symptom ScorePaolo Zaurito, Marcus Westerberg, Hans Garmo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2012
Tumor stage affects risk and prognosis of contralateral breast cancer: results from a large Swedish-population-based studyVoralak Vichapat, Hans Garmo, Marit Holmqvist, et al.
Archives of Internal Medicine|May 13, 2009
A comprehensive pharmacist intervention to reduce morbidity in patients 80 years or older: a randomized controlled trialUlrika Gillespie, Anna Alassaad, Dan Henrohn, et al.
BMJ Open|December 29, 2022
Time without PSA recurrence after radical prostatectomy as a predictor of future biochemical recurrence, metastatic disease and prostate cancer death: a prospective Scandinavian cohort studyMats Steinholtz Ahlberg, Hans Garmo, Hans-Olov Adami, et al.
The Lancet. Oncology|April 17, 2010
Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe SwedenMieke Van Hemelrijck, Jan Adolfsson, Hans Garmo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2010
Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe SwedenMieke Van Hemelrijck, Hans Garmo, Lars Holmberg, et al.
Epidemiology (Cambridge, Mass.)|May 3, 2021
An Aggregated Comorbidity Measure Based on History of Filled Drug Prescriptions: Development and Evaluation in Two Separate CohortsRolf Gedeborg, Malin Sund, Mats Lambe, et al.
European Journal of Cancer (Oxford, England : 1990)|April 14, 2011
Gamma-glutamyltransferase and risk of cancer in a cohort of 545,460 persons - the Swedish AMORIS studyMieke Van Hemelrijck, Wayel Jassem, Goran Walldius, et al.
European Urology|March 8, 2013
Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trialAnna Bill-Axelson, Hans Garmo, Lars Holmberg, et al.
Pageof 27